In most early-stage biotechs, IP belongs to whoever has time for it. Usually that is the CEO or the CSO, with an outside patent firm handling the filings. It works well enough until investors, partners or acquirers start asking detailed questions about the portfolio, and by then some of the important decisions have already been made. More companies are now bringing in a senior IP professional part time to fill the gap. You will see this called fractional IP counsel, a fractional IP adviser (or advisor) or a fractional head of IP, and the names are used loosely. What matters more is what the person actually does: advise from outside, or step into the role.
Who is making the IP decisions?
A young biotech approaching its Series A might have one patent family, often licensed from a university, and perhaps two or three follow-on applications. A clinical-stage company raising a Series B or C will have considerably more. The science is moving quickly and the team wants to publish and present. Each conference abstract is an IP decision. So is each new filing, each choice about what to keep as know-how, and the question of which claims a future partner will actually care about.
Hiring a full-time head of IP often doesn’t make sense until the pipeline is big enough to justify it. Someone senior with UK pharma experience will cost well into six figures, and there may not be a full week’s work for them. The patent firm does what it is asked to do, but it doesn’t see the board papers or know that a partnering conversation starts next quarter. The founders are trying to run the science whilst raising money. Things get decided by default.
Investors, partners and acquirers will all look at the IP closely nonetheless. It sits at the centre of any biotech deal, and whatever IP strategy the company has before a funding round, a partnership or an acquisition is the one it will be explaining in diligence.
Fractional IP adviser or head of IP?
There is a difference between someone who advises on IP and someone who is responsible for it. An adviser gives a view when asked. A head of IP sets the strategy, goes to the management meetings and makes sure the work gets done.
Independent IP consultants can be very good at the first of these, but they usually work alone, so the execution has to go somewhere else. Patent firms are set up to do the execution, one instruction at a time, without being part of the management team.
Our fractional IP counsel service is meant to cover both. One of our patent directors works as the company’s head of IP for an agreed number of days a month. They own the strategy, join the relevant meetings, and are the person the scientists ring with a question. When something needs doing, our paralegals, docketing team and document systems are there to do it, along with the AI tools we have built for this work. We have no reason to recommend work the company doesn’t need.
If you have been looking for a fractional IP adviser, the quality of the advice is what matters most. Our patent directors have spent years in-house at pharma and biotech companies and have advised on IP strategy at every stage, from the first filing to life-cycle management. That experience means our advice is practical, commercially grounded and built around what investors and partners will actually look for. Whether you need a second opinion on a single question, regular strategic advice or someone to take full responsibility for the portfolio, we can help. We are always happy to talk through what would suit you.
Having sat on the other side of the table
Our patent directors have held senior in-house IP roles at global pharma companies and at biotechs. We have carried out due diligence and IP reviews for pharma companies looking to in-license and acquire biotech assets, so we know what they look for. We have seen what makes a buyer comfortable with a portfolio and what makes them hesitate. We have also had to live with those deals for years afterwards. That is the experience we bring to a biotech’s IP strategy, well before any partner is in the room.
The science and the industry specifics of your sector matter too. A small molecule needs a different IP strategy from an antibody or a cell therapy, and oncology and autoimmune programmes generally need quite different approaches. Pharma and biotech IP is a discipline of its own, and it is the only thing we do. We work as a team, so a client with one named director still has the rest of us to draw on.
The day-to-day work
A lot of the job is routine, and that is the part an outside firm usually never sees. Publication review is a good example. Every abstract, poster and paper needs checking before it goes out, so that nothing is disclosed before it is filed. It takes a great deal of time. We use Franklin, a publication review and invention spotting tool we built ourselves, and an attorney checks everything it produces. It regularly picks up inventions nobody had thought to report.
The rest is keeping the portfolio in step with the programme as it changes, watching what competitors are filing and publishing, reporting to the board, and helping scientists understand when and how to disclose an invention and why confidentiality matters.
On freedom to operate (FTO), our view is that an early-stage company rarely needs a full, expensive FTO report. It needs someone who knows the landscape well enough to spot the patents that matter, and who can do a fuller analysis when a programme or a deal calls for one. We use our Ammonite Chart software to show the landscape in a form boards and investors can follow.
All of our AI use is covered by our professional obligations as patent attorneys. Client material is not used to train models and is not retained.
When the deal comes
If the portfolio has been reviewed and the validity risks identified in advance, diligence is far less painful. Fractional IP counsel can prepare the company for it, negotiate the IP terms of a licence or collaboration, and explain the IP position to the board and investors. For the diligence work itself we use Cassandra, our own due diligence and contract review tool, and an attorney checks everything it produces.
As the company moves into the clinic, the role picks up global filing strategy, regulatory exclusivities such as SPCs and orphan and paediatric exclusivity, and life-cycle management. We dealt with all of these in-house.
How it works in practice
We work flexibly, according to your needs. We agree a number of days a month to start with, and you only pay for the days you use. That might be a light commitment whilst the portfolio is small, more around a funding round, a partnering deal or a busy period of filing, and less again afterwards. We can review the arrangement regularly, and there is no minimum term.
We can work remotely or come in to see the team, whichever suits you. Most engagements start within a few weeks with a portfolio review and a strategy session, and the shape of the work follows from there.
We can take on the drafting and prosecution too, so that the strategy and the work sit with one team.
Where a company already has a head of IP, we can work alongside them, providing cover for leave, extra capacity or a second senior opinion for as long as they need it. They get access to our AI tools as well.
